证券记录 · 已归档季度
APGE
Apogee Therapeutics, Inc. · Healthcare · Biotechnology
8被追踪持有人
-5Δ持有人
7.45M持有股份
$437.40M报告持仓市值
+0新建仓位
−5清仓
动量输入（同类管理人）：
持有人广度 -30.0% ·
股份流向 +20.0% ·
净新建仓位 -20.0%
— 公式
集中积累 — 持股数量上升但持有人减少
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 105 | +12 | 31.81M | $4.18B | +21 | −9 |
| Q1 2026 | 96 | +7 | 41.18M | $3.45B | +13 | −6 |
| Q4 2025 | 88 | 0 | 38.24M | $2.89B | — | — |
| Q3 2025 | 17 | -2 | 25.40M | $1.01B | — | −2 |
| Q2 2025 | 16 | +1 | 22.08M | $959.13M | +1 | — |
| Q1 2025 | 12 | -1 | 10.37M | $387.41M | — | −1 |
| Q4 2024 | 13 | +4 | 9.16M | $415.03M | +4 | — |
| Q3 2024 | 8 | -5 | 7.45M | $437.40M | — | −5 |
| Q2 2024 | 13 | — | 6.20M | $244.16M | — | — |
持有人 · Q3 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 4.81M | +35.7% | $282.80M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 2 | Wellington Management ✦ | 4.81M | +35.7% | $282.80M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 3 | Wellington Management ✦ | 4.81M | +35.7% | $282.80M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 4 | Wellington Management ✦ | 4.81M | +35.7% | $282.80M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 5 | Wellington Management ✦ | 4.81M | +35.7% | $282.80M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 6 | Wellington Management ✦ | 4.81M | +35.7% | $282.80M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 4.81M | +35.7% | $282.80M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 8 | Geode Capital Management ✦ (被动) | 823.84K | +11.2% | $48.40M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Geode Capital Management ✦ (被动) | 823.84K | +11.2% | $48.40M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 758.08K | -1.3% | $44.53M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 758.08K | -1.3% | $44.53M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | Point72 Asset Management ✦ | 707.27K | +162.7% | $41.54M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 199.31K | -34.0% | $11.71M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | Millennium Management ✦ | 90.01K | -7.3% | $5.29M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 49.66K | -4.5% | $2.92M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 49.66K | -4.5% | $2.92M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Marshall Wace ✦ | 3.67K | -95.5% | $215,869 | 0.0% | ▼ Trim | 2 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| Renaissance Technologies | $6.15M | 曾为 0.0% |
| Citadel Advisors | $4.58M | 曾为 0.0% |
| Adage Capital Partners | $1.97M | 曾为 0.0% |
| Norges Bank | $476,961 | 曾为 0.0% |
| AQR Capital Management | $453,902 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 224 持有人, 77.95M 股份, $5.58B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
Jul 08
SC 13G/A — T. Rowe Price Investment Management…
Jul 08
SC 13G/A — WELLINGTON MANAGEMENT GROUP LLP
Jul 08
SC 13G/A — FMR LLC
Jun 23
SC 13D/A — Fairmount Funds Management LLC
9.8% 占股份类别 · 查看 SEC 原始申报文件 ↗
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2024 ·
方法论 ·
通过API获取此数据